ClinicalTrials.gg

Rectal Neoplasms clinical trials

Its pipeline, or its studies — you choose. Free with an account during the beta.

The registry lists 2,403 studies for Rectal Neoplasms across more than 10 countries. 589 are recruiting or about to start. 1,458 of them are mainly about Rectal Neoplasms (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-16. Counting its 2 narrower conditions too, such as Anus Neoplasms: 2,658 studies, 661 open.

ClinicalTrials.gov finds 8,556 studies for Rectal Neoplasms. How that becomes 2,403 here

This page counts the studies the registry files under Rectal Neoplasms, and those it files under no condition that list Rectal Neoplasmsthemselves. Each study its search finds is placed by how the registry filed it and by the conditions it lists. ClinicalTrials.gov counts as of Nov 16, 2026. How condition pages count

  1. 8,556Found by its condition searchIt reads the conditions a study lists and their synonyms, and also titles and keywords.
  2. −240Filed under a narrower condition, counted on its own pageAnus Neoplasms 239 · Anal Canal Carcinoma 1
  3. −205List Rectal Neoplasms as a condition, but the registry did not file them under itMost often written as “Colo-rectal Cancer” (170), “Colon Rectal Cancer” (8), and “Rectal Cancer Surgery” (6). The registry filed them under other conditions only, most often Colonic Neoplasms (184) and Colorectal Neoplasms (38).
  4. −5,709Match it another way147 name it in the title, 11 in a keyword, and 5,551 by a synonym or other text the search reads.
  5. 2,402Counted here and found by its search156 of them list Rectal Neoplasms in their own words; the registry filed them under no condition.
  6. +1
    Counted here, but its search does not find them
  7. 2,403The count on this page

Status

Completed
1,022
Recruiting
406
Status unknown
378
Terminated
199
Not yet recruiting
172
Active, not recruiting
143

Phase

Phase 2
798
Phase 1
322
Phase 3
261
Phase 4
22
Early Phase 1
13

Where

United States
780
China
462
France
160
United Kingdom
112
Italy
103
Canada
98

Who develops what

Add Rectal Neoplasms to watchlistPro · free during the betaEvery Monday by email · turn it off any time

Every program with a company-led study here in the last two years, whatever its size: 15 programs from 11 companies, 7 with this as their studies’ main aim; 7 with a live phase 3 study; 1 primary completion in the next 12 months. Compare GlaxoSmithKline, Jiangsu HengRui Medicine and Merck here →

Stage, biomarker and line of therapy are not read yet: these programs are in development here, not all in the same competitive position.

Comparator & background therapies

What other companies’ phase 2+ studies give as the comparator or the background here (its leading trial sponsor and partners left out): a sign of what new drugs are measured against, not by itself the standard of care, its prescriptions or its market.

DrugLeading trial sponsor · rightsCompanies, last 5 years
BevacizumabRecent, repeated
Evidence
  • NCT06997497 · Merck & Co., Inc · Phase 3 · live · comparator · “Bevacizumab” · registered May 2025
  • NCT06607458 · Delcath Systems Inc. · Phase 2 · live · comparator · “Trifluridine-tipiracil plus Bevacizumab Alone” · registered Sep 2024
  • NCT04607421 · Pfizer · Phase 3 · live · comparator · “Bevacizumab” · registered Oct 2020
  • NCT02305758 · AbbVie · Phase 2 · background · “Bevacizumab” · registered Dec 2014
  • NCT00819780 · Amgen · Phase 2 · comparator · “Bevacizumab” · registered Nov 2008
Hoffmann-La Roche48% of its industry studiesUS: Hoffmann-La Roche (FDA 2004) + 6 othersEU: Hoffmann-La Roche (EMA 2005) + 7 others22 studies
OxaliplatinRecent, repeatedPhase 4 trial recorded
Evidence
  • NCT07917468 · Innovent Biologics, Inc. · Phase 3 · live · background · “Oxaliplatin” · registered Oct 2026
  • NCT06997497 · Merck & Co., Inc · Phase 3 · live · background · “Oxaliplatin” · registered May 2025
  • NCT00865189 · Hoffmann-La Roche · Phase 2 · background · “Oxaliplatin” · registered Mar 2009
  • NCT00707889 · AbbVie · Phase 2 · background · “oxaliplatin” · registered Jun 2008
Sanofi35% of its industry studies22 studies

11 more in limited or earlier use — sign in to see them, free.

Programs

“Meets, by arms” reads each study’s arms: vs its arm against the therapy’s; + X vs a combination against it; added to it plus the therapy against the therapy; studied with given together only. The next primary completion is the next phase-3 study’s when there is one.

In phase 3Company
dostarlimabApproved: US 2021 · EU 2021☆ Track1 live phase-3 study: NCT07740720GlaxoSmithKline
sintilimab☆ Track1 live phase-3 study: NCT07917468Innovent Biologics, Inc.
adebrelimab☆ Track1 live phase-3 study: NCT07454720Jiangsu HengRui Medicine Co., Ltd.
Anti-CTLA-4 Monoclonal Antibody SHR-8068☆ Track1 live phase-3 study: NCT07454720Jiangsu HengRui Medicine Co., Ltd.
N-dihydrogalactochitosan☆ Track1 live phase-3 study: NCT07321847Immunophotonics, Inc.

The 5 in phase 3 with the nearest primary completion, of 15 programs — sign in to see the whole list, free: filter by phase and aim, sort by late development, direct comparisons or the next primary completion.

Primary completion in the next 12 months (1)

Live phase 2 and 3 studies of these programs. Primary completion is when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced.

  • 24 Oct 2027 est.dostarlimab · GlaxoSmithKline · Phase 2 main aimNCT06640049 A Study of Dostarlimab in Participants With Untreated Locally Advanced Rectal Cancer in China — primary endpoint: Number of Participants with Sustained Complete Clinical Response for 12 Months (cCR12) as assessed by Independent Central Review (ICR) · 23 enrolled

Read from ClinicalTrials.gov, industry-led studies. Main aim: this is the study’s judged main condition; named, not the main aim: the sponsor names it, the study is about something else; registry mapping only: only the registry’s mapping put it here. Leading trial sponsor is the company leading the most industry studies of a drug, a measure of trial activity, not of rights. US and EU rights, and Approved: from the regulators’ records (FDA’s Drugs@FDA via openFDA; EMA’s medicines data) — the holder of a marketed or authorized original, generics and other companies’ versions; not rights elsewhere, nor approval for this condition. Phase 4 trial recorded, where neither lists it: a phase 4 study exists somewhere. Not read yet: labels by indication, exclusivity, licenses, line of therapy, academic comparators, sales.

What is being tested here

Drugs under test in Rectal Neoplasms studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug classes tested here Immune checkpoint inhibitors 61 open · Antimetabolites 19 open · Angiogenesis inhibitors 6 open · Tyrosine kinase inhibitors (TKIs) 4 open · Antibody-drug conjugates (ADCs) 3 open

Coming up

181studies finish main data collection within a year10 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The 10 nearest, phase 3 first

Who these studies take

Of the 406 Rectal Neoplasms studies recruiting now, 211 (52%) set no upper age limit and 143 (35%) stop at 75 or younger. 19 (5%) take children under 18. 5 (1%) are for women only and 2 (<1%) for men only; 16 (4%) take healthy volunteers.

Recruiting studies that take each age, of 406
AgeWomenMen
1012 (3%)12 (3%)
18383 (94%)382 (94%)
30396 (98%)395 (97%)
40396 (98%)395 (97%)
50399 (98%)397 (98%)
65397 (98%)395 (97%)
75374 (92%)370 (91%)
85238 (59%)234 (58%)

Across all 2,403 studies, recruiting or not: 21% stop at 75 or younger and 1% at 65; 7% take children; 1% are for women only and 1% for men only; 4% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Rectal Neoplasms studies take

Of 242 phase 2 interventional studies under Rectal Neoplasms, half reached primary completion within 46 months of starting, counting those still running.

Start to primary completionEvery sponsorIndustryNon-industry
Phase 142 mo33–57 · 71 studies—41 mo33–56 · 52 studies
Phase 1/275 mo36–106 · 37 studies——
Phase 246 mo31–75 · 242 studies—48 mo32–80 · 228 studies
Phase 359 mo37–95 · 81 studies—76 mo38–104 · 73 studies
Interventional, no phase51 mo23–78 · 336 studies—51 mo23–78 · 329 studies
Observational45 mo24–116 · 229 studies—47 mo24–118 · 214 studies

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

What changed recently

From the registry's own updates since Oct 18, 2026.

Newly registered12

Show 7 more

Studies

Recruiting first, then most recently updated. Showing 50 of 2,403. Browse all 2,403 → or search them.